Share ownership Evaxion A/S

EVAX

US29970R3030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 18/07/2026 +04			5-day change	1st Jan Change
3.075 ^USD	-1.44%		-3.00%	-35.53%

07-17	Evaxion Presents Three-Year Clinical Efficacy Data For Personalized Cancer Vaccine EVX-01 At ESMO Congress	CI
07-12	Evaxion Presents New Preclinical Data For Cytomegalovirus Vaccine Program EVX-V1	CI

Share class: Evaxion A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	315,828,608	242,966,948 ( 76.93 %)	0	76.93 %

Major shareholders: Evaxion A/S

Name	Stocks	%	Valuation
MERCK & CO., INC. 19.22 %	1,214,126	19.22 %	4 M $
PSM Vermögensverwaltung GmbH Langen v.d.Goltz, Dr. Prinz 2.047 %	129,323	2.047 %	400 901 $
Ikarian Capital LLC 1.183 %	74,698	1.183 %	231 564 $
RATHBONES GROUP PLC 0.7239 %	45,723	0.7239 %	141 741 $
Renaissance Technologies LLC 0.621 %	39,225	0.621 %	121 598 $
Annis Gardner Whiting Capital Advisors LLC 0.4749 %	30,000	0.4749 %	93 000 $
XTX Topco Ltd. 0.3491 %	22,053	0.3491 %	68 364 $
RhumbLine Advisers LP 0.3429 %	21,659	0.3429 %	67 143 $
Stonepine Capital Management LLC 0.3121 %	19,713	0.3121 %	61 110 $
Boothbay Fund Management LLC 0.2917 %	18,426	0.2917 %	57 121 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
MERCK & CO., INC. 14.56 %	60,706,348	14.56 %	19 M $
Andreas Mattsson 1.325 %	5,524,916	1.325 %	2 M $
Marianne Søgaard 0.9264 %	3,863,115	0.9264 %	1 M $
Helena Tayton-Martin 0.5482 %	2,286,150	0.5482 %	708 707 $
Roberto Prego Pineda 0.2808 %	1,171,030	0.2808 %	363 019 $
Thomas Schmidt 0.1549 %	645,750	0.1549 %	200 183 $
Lars Holtug 0.0619 %	258,029	0.0619 %	79 989 $
Lars Wegner 0.031 %	129,139	0.031 %	40 033 $
Birgitte Rono 0.008816 %	36,765	0.008816 %	11 397 $
Jens Bitsch-Norhave 0.00057 %	2,376	0.00057 %	737 $

Breakdown by shareholder type

Merck & Co., Inc.	980.29%
Individuals	220.33%
Institutional	5.76%
Others	0.76%
Rathbones Group Plc	0.72%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	984.41%
Individuals	220.33%
Germany	2.05%
United Kingdom	0.72%
Cayman Islands	0.35%

Based on 1000 largest holdings

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company